It has been shown that both tau and amyloid have synergic effects on mitochondrial dysfunction [126], suggesting that a biomarker timeline based on mitochondrial pathology might be more accurate in AD and would reconcile with Braak staging of pathology that has been well supported by neuroimaging studies. The gene discussed is MAPT; the disease is Alzheimer disease.